TX-000045 is under clinical development by Tectonic Therapeutic Inc and currently in Phase I for Pulmonary Hypertension. According to GlobalData, Phase I drugs for Pulmonary Hypertension have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TX-000045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TX-000045 overview

TX-000045 is under development for the treatment of congestive heart failure and pulmonary hypertension. It acts by targeting relaxin receptor 1 (RXFP1). The drug candidate is administered through intravenous and subcutaneous route. It is being developed based on GEODe platform.

Tectonic Therapeutic Inc overview

Tectonic Therapeutic Inc (Tectonic) discovers antibodies and other biologic drugs?targeting G-protein Coupled Receptors (GPCRs). Tectonic is headquartered in Watertown, Massachusetts, the US.

For a complete picture of TX-000045’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.